person · Reporting owner

SHAMIR NACHUM

Disclosed activity across 7 companies

Tapewire entity: 33961
SEC CIK: 0001622164

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cactus Acquisition Corp. 1 LtdCCTSU · Entity 88589	Director	October 28, 2021	November 03, 2021
MediWound Ltd.MDWD · Entity 296	Director	June 03, 2026	June 04, 2026
STRATA Skin Sciences, Inc.SSKN · Entity 72980	Director	July 05, 2023	July 07, 2023
Stereotaxis, Inc.STXS · Entity 6577	Director	July 01, 2026	July 01, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cactus Acquisition Corp. 1 Ltd

Report date October 28, 2021 · Filed November 03, 2021

This filing explicitly reported no securities owned.

MediWound Ltd.

Report date June 03, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	55,815	Ending reported balance After 2026-06-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-03 · Purchase · Acquired 175 · Balance 49,990 Row 2 · 2026-06-03 · Purchase · Acquired 5,825 · Balance 55,815
Ordinary sharesSEC Table I · non-derivative	Direct	1,200	Reported balance Holding disclosure · report date 2026-06-03 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,200 F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Series A WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $13.48 · Expires 2026-11-28	Direct	16,336	Reported balance Holding disclosure · report date 2026-06-03 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 16,336
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2032-08-17	Direct	28,571	Reported balance Holding disclosure · report date 2026-06-03 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 28,571 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2033-05-30	Direct	11,800	Reported balance Holding disclosure · report date 2026-06-03 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 11,800 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2034-02-26	Direct	12,570	Reported balance Holding disclosure · report date 2026-06-03 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 12,570 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.54 · Expires 2035-02-11	Direct	9,200	Reported balance Holding disclosure · report date 2026-06-03 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 9,200 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2036-03-04	Direct	10,000	Reported balance Holding disclosure · report date 2026-06-03 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 10,000 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

STRATA Skin Sciences, Inc.

Report date July 05, 2023 · Filed July 07, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
SSKN Common StockSEC Table I · non-derivative	Direct	289,871	Reported balance After 2023-07-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-07-05 · Grant · Acquired 38,835 · Balance 289,871 F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period.

Stereotaxis, Inc.

Report date July 01, 2026 · Filed July 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	179,327	Reported balance After 2026-07-01 transaction · row 1 1 source row Row 1 · 2026-07-01 · Grant · Acquired 43,103 · Balance 179,327 F1: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents).

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents).

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

COGENTIX MEDICAL INC /DE/

Report date April 23, 2018 · Filed April 23, 2018

Section 16 reporting ended · disclosed 2018-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-04-23 transaction · row 1 1 source row Row 1 · 2018-04-23 · Disposition to issuer · Disposed 159,172 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"), all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration") upon the effectiveness of the merger of Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"), all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration") upon the effectiveness of the merger of Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC.

IsoPlexis Corp

Report date March 21, 2023 · Filed March 21, 2023

Section 16 reporting ended · disclosed 2023-03-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2023-03-21 transaction · row 1 1 source row Row 1 · 2023-03-21 · Disposition to issuer · Disposed 50,253 · Balance 0 F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2032-08-22	Direct	0	Reported balance After 2023-03-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-21 · Disposition to issuer · Disposed 196,842 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option reported in this Form 4 that was (a) vested and unexercised or (b) vested solely as a result of the consummation of the merger pursuant to the Merger Agreement was, in each case, exercisable prior to the effective time of such merger and, to the extent unexercised at such effective time, canceled for no consideration. F3: Vests in 36 equal monthly installments from the grant date (August 22, 2022)

Filing footnotes · ownership attribution and instrument terms

F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions.

F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option reported in this Form 4 that was (a) vested and unexercised or (b) vested solely as a result of the consummation of the merger pursuant to the Merger Agreement was, in each case, exercisable prior to the effective time of such merger and, to the extent unexercised at such effective time, canceled for no consideration.

F3: Vests in 36 equal monthly installments from the grant date (August 22, 2022)

LUMINEX CORP

Report date July 14, 2021 · Filed July 15, 2021

Section 16 reporting ended · disclosed 2021-07-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2021-07-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-07-14 · Disposition to issuer · Disposed 152,372 · Balance 88,798 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2: This amount includes 515 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021. Row 2 · 2021-07-14 · Disposition to issuer · Disposed 88,798 · Balance 0 F3: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes).
Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2023-03-22	Direct	Reported balance After 2021-07-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-14 · Disposition to issuer · Disposed 177,880 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.
Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2023-03-22	Direct	Reported balance After 2021-07-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-14 · Disposition to issuer · Disposed 106,728 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.
Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.04 · Expires 2024-03-10	Direct	Reported balance After 2021-07-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-14 · Disposition to issuer · Disposed 334,896 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.
Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.98 · Expires 2025-03-12	Direct	Reported balance After 2021-07-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-14 · Disposition to issuer · Disposed 140,815 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.
Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.09 · Expires 2027-03-12	Direct	Reported balance After 2021-07-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-07-14 · Disposition to issuer · Disposed 648,686 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.
Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2026-03-12	Direct	Reported balance After 2021-07-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-14 · Disposition to issuer · Disposed 129,520 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share.

F2: This amount includes 515 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021.

F3: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes).

F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 16, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	Exercise / conversionStock Option (Right To Buy) · Derivative	125,000	$0.00 Strike: $21.10	$0.00	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · derivative · entry 9 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2021-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 16, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	SaleCommon Stock	125,000	$31.00	$3,875,000.00	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · nonDerivative · entry 6 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,024 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on February 28, 2020 (the "Trading Plan"). The Trading Plan covered options that were otherwise set to expire in 2021. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the Trading Plan was adopted. Read SEC document
April 16, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	Exercise / conversionCommon Stock	125,000	$21.10	$2,637,500.00	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · nonDerivative · entry 5 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 15, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	Exercise / conversionStock Option (Right To Buy) · Derivative	79,092	$0.00 Strike: $21.10	$0.00	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · derivative · entry 8 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 79,092 shares Expires 2021-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 15, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	SaleCommon Stock	79,092	$30.00	$2,372,760.00	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · nonDerivative · entry 4 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,024 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on February 28, 2020 (the "Trading Plan"). The Trading Plan covered options that were otherwise set to expire in 2021. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the Trading Plan was adopted. Read SEC document
April 15, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	Exercise / conversionCommon Stock	79,092	$21.10	$1,668,841.20	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · nonDerivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 14, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	Exercise / conversionStock Option (Right To Buy) · Derivative	45,908	$0.00 Strike: $21.10	$0.00	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · derivative · entry 7 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,092 Underlying: Common Stock · 45,908 shares Expires 2021-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 14, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	SaleCommon Stock	45,908	$30.00	$1,377,240.00	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,024 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on February 28, 2020 (the "Trading Plan"). The Trading Plan covered options that were otherwise set to expire in 2021. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the Trading Plan was adopted. Read SEC document
April 14, 2020 Filed Apr 16, 2020 11:26 UTC	LUMINEX CORP LMNX · Entity 137318	Exercise / conversionCommon Stock	45,908	$21.10	$968,658.80	Disclosure SEC source: 0001033905-20-000036 · wf-form4_158705074551335.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 12, 2020 Filed Mar 13, 2020 16:30 UTC	LUMINEX CORP LMNX · Entity 137318	GrantCommon Stock · Derivative	129,520	$24.43 Strike: $24.43	$3,164,173.60	Disclosure SEC source: 0001033905-20-000026 · wf-form4_158413138497094.xml · derivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,520 Underlying: Common Stock · 129,520 shares Expires 2026-03-12 F4 · shares: The Board of Directors of Luminex Corporation determined the level of performance and number of shares earned for this performance option. The option will vest annually in four equal installments beginning 03/12/2020. Read SEC document
March 12, 2020 Filed Mar 13, 2020 16:30 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	7,172	$23.09	$165,601.48	Disclosure SEC source: 0001033905-20-000026 · wf-form4_158413138497094.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,024 F2 · shares: This disposition relates to withholding for taxes on 19,560 vesting shares associated with a previously reported issuance. F3 · balance_after: This balance includes a total of 349 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on November 29, 2019. Read SEC document
March 11, 2020 Filed Mar 13, 2020 16:30 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	1,687	$27.11	$45,734.57	Disclosure SEC source: 0001033905-20-000026 · wf-form4_158413138497094.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,847 F1 · shares: This disposition relates to withholding for taxes on 6,929 vesting shares associated with a previously reported issuance. Read SEC document
November 22, 2019 Filed Nov 26, 2019 16:36 UTC	STRATA Skin Sciences, Inc. SSKN · Entity 72980	GrantSSKN Common Stock	16,260	$0.00	$0.00	Disclosure SEC source: 0001051514-19-000130 · form4.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,075 F1 · security: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on November 22, 2019 at the closing price of $2.46. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. F2 · balance_after: Includes 28,986 fully vested Restricted Stock Units granted on June 8, 2018 and previously reported on Table II. Read SEC document
November 11, 2019 Filed Nov 12, 2019 12:23 UTC	LUMINEX CORP LMNX · Entity 137318	PurchaseCommon Stock	5,000	$19.30	$96,482.00	Disclosure SEC source: 0001033905-19-000089 · wf-form4_157357939712159.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,534 Read SEC document
August 26, 2019 Filed Aug 27, 2019 15:27 UTC	LUMINEX CORP LMNX · Entity 137318	PurchaseCommon Stock	5,000	$19.71	$98,528.00	Disclosure SEC source: 0001033905-19-000074 · wf-form4_156693405982932.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,534 F1 · balance_after: This balance includes 593 shares obtained on May 31, 2019 under the Luminex Corporation Employee Stock Purchase Plan. Read SEC document
March 12, 2019 Filed Mar 14, 2019 17:25 UTC	LUMINEX CORP LMNX · Entity 137318	GrantStock Option (Right To Buy) · Derivative	140,815	$21.98 Strike: $21.98	$3,095,113.70	Disclosure SEC source: 0001033905-19-000025 · wf-form4_155259873450503.xml · derivative · entry 4 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,815 Underlying: Common Stock · 140,815 shares Expires 2025-03-12 F3 · shares: The Board of Directors of Luminex Corporation determined the level of performance and number of shares earned for this performance option. The option will vest annually in four equal installments beginning 03/12/19. Read SEC document
March 12, 2019 Filed Mar 14, 2019 17:25 UTC	LUMINEX CORP LMNX · Entity 137318	GrantCommon Stock	32,746	$24.43	$799,984.78	Disclosure SEC source: 0001033905-19-000025 · wf-form4_155259873450503.xml · nonDerivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,941 Read SEC document
March 12, 2019 Filed Mar 14, 2019 17:25 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	2,769	$24.43	$67,646.67	Disclosure SEC source: 0001033905-19-000025 · wf-form4_155259873450503.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,195 F2 · shares: This disposition relates to withholding for taxes on 11,373 vesting shares associated with a previously reported issuance. Read SEC document
March 11, 2019 Filed Mar 14, 2019 17:25 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	1,687	$24.14	$40,724.18	Disclosure SEC source: 0001033905-19-000025 · wf-form4_155259873450503.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,964 F1 · shares: This disposition relates to withholding for taxes on 6,929 vesting shares associated with a previously reported issuance. Read SEC document
December 28, 2018 Filed Dec 29, 2016 16:33 UTC	COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360	GrantCommon Stock	100,000	$0.00	$0.00	Disclosure SEC source: 0001437749-16-043930 · rdgdoc.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: This Restricted Stock Award vests in full six months from the date of grant. Read SEC document
October 15, 2018 Filed Oct 17, 2018 11:36 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	9,837	$27.23	$267,861.51	Disclosure SEC source: 0001033905-18-000086 · wf-form4_153979060195798.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,651 F1 · shares: This disposition relates to withholding for taxes on 25,000 vesting shares associated with a previously reported issuance. F2 · balance_after: This balance includes 1,177 shares obtained May 31, 2018 under the Luminex Corporation Employee Stock Purchase Plan. Read SEC document
June 08, 2018 Filed Jun 12, 2018 10:47 UTC	STRATA Skin Sciences, Inc. SSKN · Entity 72980	GrantSTRATA Restricted Stock Units · Derivative	28,986	$0.00 Strike: $2.07	$0.00	Disclosure SEC source: 0001140361-18-028172 · doc1.xml · derivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,986 Underlying: Common Stock · 28,986 shares Expires 2028-06-08 F1 · derivative.exercise_date: Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. Read SEC document
April 23, 2018 Filed Apr 23, 2018 17:13 UTC	COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360	Disposition to issuerCommon Stock	159,172	$3.85	$612,812.20	Disclosure SEC source: 0001437749-18-007496 · rdgdoc.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"), all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration") upon the effectiveness of the merger of Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC. Read SEC document
March 12, 2018 Filed Mar 15, 2018 13:07 UTC	LUMINEX CORP LMNX · Entity 137318	GrantCommon Stock	45,495	$21.98	$999,980.10	Disclosure SEC source: 0001033905-18-000025 · wf-form4_152113363219452.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,311 Read SEC document
March 11, 2018 Filed Mar 15, 2018 13:07 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	1,687	$21.73	$36,658.51	Disclosure SEC source: 0001033905-18-000025 · wf-form4_152113363219452.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,816 F1 · shares: This disposition relates to withholding for taxes on 6,929 vesting shares associated with a previously reported issuance. Read SEC document
March 10, 2018 Filed Mar 15, 2018 13:07 UTC	LUMINEX CORP LMNX · Entity 137318	GrantStock Option (Right To Buy) · Derivative	334,896	$18.04 Strike: $18.04	$6,041,523.84	Disclosure SEC source: 0001033905-18-000025 · wf-form4_152113363219452.xml · derivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,896 Underlying: Common Stock · 334,896 shares Expires 2024-03-10 F2 · shares: The Board of Directors of Luminex Corporation determined the level of performance and the number of shares earned for this performance option. The option will vest in four equal installments on the first, second, third and fourth anniversary of the 3/10/2017 grant date. Read SEC document
October 16, 2017 Filed Oct 17, 2017 16:38 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	10,487	$20.55	$215,507.85	Disclosure SEC source: 0001033905-17-000088 · wf-form4_150827268531615.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,503 F1 · shares: This disposition relates to withholding for taxes on 25,000 vesting shares associated with a previously reported issuance. F2 · balance_after: Includes 1,264 shares acquired under the Employee Stock Purchase Plan on May 31, 2017. Read SEC document
May 23, 2017 Filed May 24, 2017 17:16 UTC	COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360	GrantCommon Stock	59,172	$0.00	$0.00	Disclosure SEC source: 0001437749-17-009996 · rdgdoc.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,172 F1 · shares: This Restricted Stock Award vests in full six months from the date of grant. F2 · balance_after: Total holdings include restricted stock awards. Read SEC document
March 10, 2017 Filed Mar 14, 2017 16:01 UTC	LUMINEX CORP LMNX · Entity 137318	GrantCommon Stock	27,716	$0.00	$0.00	Disclosure SEC source: 0001033905-17-000037 · wf-form4_148952165636768.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,726 Read SEC document
February 24, 2017 Filed Feb 28, 2017 12:40 UTC	LUMINEX CORP LMNX · Entity 137318	GrantStock Option (Right To Buy) · Derivative	106,728	$0.00 Strike: $19.13	$0.00	Disclosure SEC source: 0001033905-17-000026 · wf-form4_148830360474748.xml · derivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,728 Underlying: Common Stock · 106,728 shares Expires 2023-03-22 F1 · date: On February 24, 2017, the Board of Directors of Luminex Corporation determined the level of performance and the number of shares earned for this performance option. The option will vest in four equal installments on the first, second, third and fourth anniversary of the 3/22/2016 grant date. Read SEC document
November 03, 2016 Filed Nov 7, 2016 09:26 UTC	LUMINEX CORP LMNX · Entity 137318	PurchaseCommon Stock	6,000	$18.22	$109,297.80	Disclosure SEC source: 0001033905-16-000196 · wf-form4_147852874973186.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,010 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.20 to $18.27 inclusive. Mr. Shamir undertakes to provide to Luminex Corporation, any security holder of Luminex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1 to this Form 4. Read SEC document
October 14, 2016 Filed Oct 18, 2016 15:03 UTC	LUMINEX CORP LMNX · Entity 137318	Tax withholdingCommon Stock	9,636	$22.16	$213,533.76	Disclosure SEC source: 0001033905-16-000188 · wf-form4_147681736733876.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,010 F1 · balance_after: Includes 1,506 shares acquired under the Employee Stock Purchase Plan on November 30, 2015 and 1,140 shares acquired under the Employee Stock Purchase Plan on May 31, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.